TNFRSF9 and neoplasm: Much evidence demonstrate the promising effects for anti-CD137 mAbs in the treatment of mice bearing established tumors [23,24]; this is not only achieved by agonist antibodies but also by dimeric RNA aptamers or tumor cells expressing a surface-attached anti-CD137 single chain antibody [25,26].